3 results
Approved WMOPending
To evaluate the efficacy of AD 923 in comparison to MSIR in the management of breakthrough pain in subjects with malignicies who are taking a stable dose of background opioids.
Approved WMOPending
To obtain more information about the efficacy and tolerability of AD 923 in long-term management of breakthrough pain in subjects with malignicies who are taking a stable dose of background opioids and receive therapy for BTP.
Approved WMOCompleted
Primary objective: To assess the PK of oral FT011 in participants with diffuse SSc.Secondary objectives: • To assess the safety and tolerability of oral FT011 compared to placebo in participants with diffuse SSc.• To evaluate the short-term efficacy…